Teatime: epigallocatechin gallate targets fibroblast–epithelial cell crosstalk to combat lung fibrosis

Epigallocatechin gallate (EGCG) is a polyphenol plant metabolite abundant in tea that has demonstrated antifibrotic properties in the lung. In this issue of the JCI, Cohen, Brumwell, and colleagues interrogated the mechanistic action of EGCG by investigating lung biopsies of patients with mild interstitial lung disease (ILD) who had undergone EGCG treatment. EGCG targeted the WNT inhibitor SFRP2, which was enriched in fibrotic fibroblasts and acted as a TGF-β target, with paracrine effects leading to pathologic basal metaplasia of alveolar epithelial type 2 cells. This study emphasizes the epithelial-mesenchymal trophic unit as a central signaling hub in lung fibrosis. Understanding and simultaneous targeting of interlinked signaling pathways, such as TGF-β and WNT, paves the road for future treatment options for pulmonary fibrosis.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Investigation
Published
2024-09-16
DOI
https://doi.org/10.1172/jci183970
Citations
4
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
1.68

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Teatime: epigallocatechin gallate targets fibroblast–epithelial cell crosstalk to combat lung fibrosis

Olivier Burgy, Mélanie Königshoff
4 citations
Journal of Clinical Investigation
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
1.68
article

Teatime: epigallocatechin gallate targets fibroblast–epithelial cell crosstalk to combat lung fibrosis

Olivier Burgy, Mélanie Königshoff
article en
4 citations

Abstract

Epigallocatechin gallate (EGCG) is a polyphenol plant metabolite abundant in tea that has demonstrated antifibrotic properties in the lung. In this issue of the JCI, Cohen, Brumwell, and colleagues interrogated the mechanistic action of EGCG by investigating lung biopsies of patients with mild interstitial lung disease (ILD) who had undergone EGCG treatment. EGCG targeted the WNT inhibitor SFRP2, which was enriched in fibrotic fibroblasts and acted as a TGF-β target, with paracrine effects leading to pathologic basal metaplasia of alveolar epithelial type 2 cells. This study emphasizes the epithelial-mesenchymal trophic unit as a central signaling hub in lung fibrosis. Understanding and simultaneous targeting of interlinked signaling pathways, such as TGF-β and WNT, paves the road for future treatment options for pulmonary fibrosis.

Journal of Clinical InvestigationVol. 134(18)
Inserm (FR), University of Pittsburgh (US), Université de Bourgogne (FR), Geriatric Research Education and Clinical Center (US), VA Pittsburgh Healthcare System (US), Maison des Sciences sociales et des Humanités de Dijon (FR)
University of Pittsburgh, Agence Nationale de la Recherche, National Institutes of Health, Medical Center, University of Pittsburgh
Good health and well-being
Openalex Percentile: Top 15%
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
1.68
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Teatime: epigallocatechin gallate targets fibroblast–epithelial cell crosstalk to combat lung fibrosis — Olivier Burgy, Mélanie Königshoff · Journal of Clinical Investigation (2024) | TGRS Research Map | TGRS